A Method for the Prediction of Clinical Outcome Using Diffusion Magnetic Resonance Imaging: Application on

Chih-Chien Tsai1, Yu-Chun Lin2,3, Shu-Hang Ng2,3

  • 1Healthy Aging Research Center, Chang Gung University, Taoyuan 33302, Taiwan.

Insights

Baseline diffusion MRI can predict Parkinson's disease (PD) clinical outcomes two years in advance. This method uses magnetic resonance imaging to forecast disease severity and quality of life changes in PD patients.

Area of Science:

  • Neurology
  • Radiology
  • Biomedical Engineering

Background:

  • Early prediction of clinical outcomes in Parkinson's disease (PD) is crucial for effective management.
  • Current methods may not fully capture the progressive nature of PD at the individual level.

Purpose of the Study:

  • To develop and validate a method using baseline magnetic resonance imaging (MRI) diffusion parameters to predict 2-year clinical outcomes in PD patients.
  • To identify specific diffusion parameters and brain regions predictive of PD progression.

Main Methods:

  • Diffusion tensor imaging (DTI) was performed on 82 PD patients.
  • Mean diffusivity (MD) and fractional anisotropy (FA) were analyzed using least absolute shrinkage and selection operator (LASSO) regression.
  • A stepwise multivariate regression model with cross-validation and independent dataset validation was employed to predict Unified Parkinson's Disease Rating Scale (UPDRS) scores.

Main Results:

  • The model, utilizing 13 diffusion parameters (including MD in lingual gyrus and FA in cerebellum regions), accurately predicted 2-year UPDRS scores (adjusted R² = 0.76) in a blind validation dataset.
  • Key predictive features included mean diffusivity in the lingual gyrus and cerebellum, and fractional anisotropy in the rolandic operculum and cerebellum.

Conclusions:

  • Baseline diffusion MRI parameters show potential for predicting individual 2-year clinical outcomes in Parkinson's disease.
  • This non-invasive imaging approach could aid in personalized treatment strategies and clinical trial design for PD.